Dr. Yardley on tNACity Trial for Triple-Negative Breast Cancer

Denise Yardley, MD
Published: Thursday, Jan 12, 2017



Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the tNACity trial for patients with triple-negative breast cancer.

The tNACity trial is a first-line study where patients will be randomized into 1 of 3 arms. The treatment arm is evaluating abraxane which has had an increase of signal activity in these patients. Due to the results of previous trials, one of the control arms was iniparab gemcitabine/carboplatin. The doublet arm was gemcitabine/abraxane and carboplatin/abraxane.

There is controversy surrounding the doublet therapy, according to Yardley, but with the need for responses in patients due to the aggressive relapses and short disease-free intervals, it has become more accepted, particularly in the triple-negative patients.
 


Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the tNACity trial for patients with triple-negative breast cancer.

The tNACity trial is a first-line study where patients will be randomized into 1 of 3 arms. The treatment arm is evaluating abraxane which has had an increase of signal activity in these patients. Due to the results of previous trials, one of the control arms was iniparab gemcitabine/carboplatin. The doublet arm was gemcitabine/abraxane and carboplatin/abraxane.

There is controversy surrounding the doublet therapy, according to Yardley, but with the need for responses in patients due to the aggressive relapses and short disease-free intervals, it has become more accepted, particularly in the triple-negative patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x